|
| Press Releases |
|
 |
|
| Wednesday, December 20, 2023 |
|
|
欧康维视生物： OT-703获批于香港上市，为糖尿病性黄斑水肿患者治疗带来新选择 |
| 中国领先眼科医药平台公司 — 欧康维视生物（「欧康维视」或「公司」，连同其附属公司，统称「集团」，股份代号：1477）欣然宣布，集团旗下OT-703（ILUVIEN(R)，氟轻松玻璃体植入剂） more info >> |
|
|
歐康維視生物： OT-703獲批於香港上市，為糖尿病性黃斑水腫患者治療帶來新選擇 |
| 中國領先眼科醫藥平台公司 — 歐康維視生物（「歐康維視」或「公司」，連同其附屬公司，統稱「集團」，股份代號：1477）欣然宣佈，集團旗下OT-703（ILUVIEN(R)，氟輕鬆玻璃體植入劑） more info >> |
|
|
Ocumension Therapeutics: The Approval Received For Marketing OT-703 In Hong Kong, A New Option For Patients With Diabetic Macular Edema |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, is pleased to announce that, OT-703 (ILUVIEN(R), fluocinolone intravitreal implant), an injectable more info >> |
|
| Thursday, August 24, 2023 |
|
|
欧康维视公布2023年中期业绩 |
| 中国领先眼科医药平台公司 — 欧康维视生物 (「欧康维视」或「公司」，连同其附属公司，统称「集团」)（股份代号：1477.HK），今天公布截至2023年6月30日止六个月（「报告期内」）中期业绩。 more info >> |
|
|
歐康維視公佈2023年中期業績 |
| 中國領先眼科醫藥平台公司 — 歐康維視生物 (「歐康維視」或「公司」，連同其附屬公司，統稱「集團」)（股份代號：1477.HK），今天公佈截至2023年6月30日止六個月（「報告期內」）中期業績。 more info >> |
|
|
Ocumension Therapeutics Announces 2023 Interim Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, announced its interim results for the six months ended 30 June 2023 ("the Period") today. more info >> |
|
| Thursday, March 30, 2023 |
|
|
欧康维视公布2022年全年业绩 |
| 中国领先眼科医药平台公司 — 欧康维视生物 (「欧康维视」或「公司」，连同其附属公司，统称「集团」)（股份代号：1477.HK），今天公布截至2022年12月31日止年度（「年度」）全年业绩。 more info >> |
|
|
歐康維視公佈2022年全年業績 |
| 中國領先眼科醫藥平台公司 — 歐康維視生物 (「歐康維視」或「公司」，連同其附屬公司，統稱「集團」)（股份代號：1477.HK），今天公佈截至2022年12月31日止年度（「年度」）全年業績。 more info >> |
|
|
Ocumension Therapeutics Announces 2022 Annual Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, announced its annual results for the year ended 31 December 2022 today. more info >> |
|
| Monday, March 13, 2023 |
|
|
欧康维视获纳入沪港通及深港通名单 |
| 中国领先眼科医药平台公司 — 欧康维视生物（「欧康维视」或「公司」，连同其附属公司，统称「集团」，股份代号：1477）欣然宣布，集团在香港联合交易所有限公司（「香港交易所」）发行的普通股正式被纳入港股通下沪港通及深港通股票名单，并于3月13日起生效。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Hola Prime Plans to Enter Futures Trading to Solve One of Finance's Most Persistent Problems: Complexity
May 23, 2025 20:00: JST
|
|
|
Hola Prime Plans to Enter Futures Trading to Solve One of Finance's Most Persistent Problems: Complexity
May 23, 2025 19:00 HKT/SGT
|
|
|
sureWin Nominated for Best iGaming Platform 2025 in SiGMA Awards
May 23, 2025 19:00: JST
|
|
|
sureWin Nominated for Best iGaming Platform 2025 in SiGMA Awards
May 23, 2025 19:00 HKT/SGT
|
|
|
Fujitsu and Tokai National Higher Education and Research System utilize AI to accelerate clinical research and tackle 'drug loss' in Japan
May 23, 2025 17:29 JST
|
|
|
三菱商事、経営戦略2027の実現に向けた人事領域の取り組みについて発表
May 23, 2025 14:00: JST
|
|
|
Lockheed Martin and Fujitsu Strengthen Japan Industry Collaboration with SPY-7 Supplier Selection and Strategic Agreements
May 23, 2025 13:36 JST
|
|
|
NIED, Fujitsu, SDS and Mitsubishi Electric sign joint research agreement to advance Japan Disaster Charter operational framework
May 23, 2025 13:35 JST
|
|
|
Honda Expands Production Capacity by Adding New Production Line at Fourth Motorcycle Plant in India
May 23, 2025 12:17 JST
|
|
|
Honda Reaches 500 Million-Unit Milestone in Cumulative Global Motorcycle Production
May 23, 2025 11:32 JST
|
|
|
東海国立大学機構と富士通、生成AIを用いた診療データの活用により治験候補患者の選定に貢献
May 23, 2025 10:30: JST
|
|
|
Five Toyota Group Companies to Accelerate Skill Development and Innovation in AI and Software
May 23, 2025 10:51 JST
|
|
|
52TOYS即將赴港上市 打造IP玩具新標桿
May 23, 2025 07:59 HKT/SGT
|
|
|
52TOYS即将赴港上市 打造IP玩具新标杆
May 23, 2025 07:36 HKT/SGT
|
|
|
DCLI Drives Fleet Efficiencies with BlackBerry Radar Deployment Across 100,000 Chassis
May 22, 2025 19:56 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
